SEC Comment Letter 0000000000-23-010437 to AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: Sept. 21, 2023 · CIK: 0001644963 · Accession: 0000000000-23-010437
AI Filing Summary & Sentiment
File numbers found in text: 333-274562
Letter
United States securities and exchange commission logo September 21, 2023 Alexandra MacLean, M.D. Chief Executive Officer Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Re:Avenue Therapeutics, Inc. Registration Statement on Form S-1 Filed September 18, 2023 File No. 333-274562 Dear Alexandra MacLean: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David S. Wolpa
Show Raw Text
United States securities and exchange commission logo
September 21, 2023
Alexandra MacLean, M.D.
Chief Executive Officer
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
Re:Avenue Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 18, 2023
File No. 333-274562
Dear Alexandra MacLean:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David S. Wolpa